Articles

 Pegaferon® – Safety and Ef cacy of Locally Manufactured Pegylated Interferon in Hepatitis C Patients

 Pegaferon® – Pegaferon in hepatitis C Results of a Multicenter Study

 Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

 Pegaferon® – Locally Produced Peginterferon As An Opportunity to

 Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C

 Treatment Outcome in Chronic Hepatitis C Infection A Four Years Survey Among Iranian Patients

 PDferon® – Successful interferon desensitization in a patient with

 PDferon® – Preliminary Report of Interferon α2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C

 PDferon® – Interferon –alpha 2b (PDferon B®) in Treatment of HBeAgnegative

 PDferon® – Efficacy and safety of Interferon-alpha (PDferon B®)

 Clinical outcome of interferon and ribavirin combination treatment in hepatitis C virus infected patients with congenital bleeding disorders in Iran

 Combination therapy with interferon and ribavirin for chronic hepatitis C infection in beta-thalassaemia major

 Combination_Therapy_of_Interferon-alpha (PDferon B®) and Ribavirin for Chronic Hepatitis C

 Conventional Versus Pegylated Interferons in Treatment of HCV patients

 EFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C

 Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C

 Hepatitis B virus DNA level as predictor of response to therapy with interferon-alpha-2b (PDferon) in chronic hepatitis B infection

 Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemialymphoma (ATL)

 Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b

 PDpoietin in Comparison With Eprex in Treatment of Anemic

PDpoetin immunogenicity compared with Eprex ,in patients undergoing maintenance hemodialysis

 Safety and efficacy of PDpoetin for management of anemia in patients with end stage renal disease on maintenance hemodialysis results from a phase IV clinical trial

 Hemoglobin and Hematocrit Rise in End-Stage Renal Disease (ESRD) with PDpoetin Results of a Phase Ш, Multicenter Clinical Trial

 Beneficial Erythropoietic Effects of Recombinant Human Erythropoietin in Very Low‑Birth Weight Infants A Single‑Center Randomized Double‑Blinded Placebo‑Controlled Trial

 Does High Dose Erythropoietin administration reduce ischemic stroke complications

 Effect of Erythropoietin on Kidney Allograft Survival Early Use After Transplantation

 Effects of Erythropoietin and GCSF on Traumatic Osteonecrosis of the Femoral Head in Rabbits

 Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction

 Neuroprotective Effects of Erythropoietin in Acute Ischemic Stroke

 Protective Role of Recombinant Human Erythropoietin in Kidney and Lung Injury Following Renal Bilateral Ischemia‑Reperfusion in Rat Model

 The Ovario-Protective Effect of Erythropoietin against Oxidative Damage Associated with Reperfusion Following Ovarian Torsion in Rat

 Erythropoietin plus Methylprednisolone or Methylprednisolone in the Treatment of Acute Spinal Cord Injury a Preliminary Report

Human Erythropoietin Effect in Postoperative Visual Loss Following Spine Surgery A Case Report 

 Recombinant human erythropoietin reduces plasminogen activator inhibitor and ameliorates pro-inflammatory responses following trauma

 The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT a double-blind, randomized, placebo controlled

 Effect of recombinant erythropoietin in serum paraoxonase activity level,Total antioxidant and lipid peroxidation in Rat.